Last edited Tue, 10 Jun 2025

Glioblastoma (GBM) is the most aggressive and lethal form of primary brain tumor in adults, classified as a grade IV astrocytoma by the World Health Organization. According to data from the central brain tumor registry, glioblastoma accounts for a significant percentage of all primary brain tumors diagnosed annually, with notable demographic trends.

Recent integrative spatial analyses have revealed that GBM is not a uniform mass but a multi-layered, spatially organized tumor composed of distinct cellular states and microenvironments. These layers are shaped by hypoxia and include interactions between neural progenitor-like cells, mesenchymal-like cells, and oligodendrocyte precursor-like cells. Key signaling pathways like EGFR/PI3K/AKT/mTOR, MAPK, Wnt, and NF-κB, are frequently dysregulated, driving tumor growth, angiogenesis, immune evasion, and resistance to apoptosis.

Get your interactive glioblastoma pathway

Glioblastoma biochemistry

GBM is characterized by profound inter- and intra-tumoral heterogeneity, driven by complex alterations in genetic, epigenetic, and transcriptomic landscapes. Among the most prominent features is the frequent alteration of the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that is amplified or mutated in approximately 40-50% of glioblastoma cases. EGFR gene amplification and mutation result in persistent activation of downstream signaling, fueling tumor cell proliferation, survival, and resistance to therapy. Another critical pathway commonly disrupted in GBM is the PI3K/AKT/mTOR pathway, with mutations in the PIK3CA gene and other components occurring in 10-20% of cases. These alterations not only promote tumor growth and survival but also contribute to the development of resistance to targeted therapies, complicating treatment strategies. The interplay between these key signaling pathways and other molecular changes shapes the aggressive biology of GBM and is closely linked to poor patient prognosis. The importance of molecular biomarkers, such as MGMT promoter methylation status, is increasingly recognized in guiding treatment decisions for glioblastoma. Understanding tumor biology, including the genetic and molecular mechanisms underlying diffuse glioma and diffuse gliomas, is essential for developing targeted therapies and improving patient outcomes.

Other key signaling pathways

Beyond the well-characterized PI3K/AKT/mTOR and EGFR pathways, several other key signaling pathways are frequently dysregulated in glioblastoma, further contributing to its aggressive behavior. The Wnt signaling pathway plays a pivotal role in regulating cell proliferation and differentiation, while the NF-κB pathway is central to inflammation and immune response modulation within the tumor microenvironment. The TGF-β pathway influences cell growth, differentiation, and programmed cell death, and its aberrant activation is associated with enhanced tumor invasiveness and resistance to therapy. Alterations in these pathways—such as mutations, amplifications, or abnormal activation—are observed in a significant proportion of GBM cases, ranging from 10% to 50%. Preclinical studies have demonstrated that targeting these signaling pathways can suppress tumor cell growth and improve treatment responses in GBM models. As a result, multiple clinical trials are currently underway to evaluate the efficacy of novel targeted therapies aimed at these pathways, offering hope for more effective treatment options for glioblastoma patients in the future.

Understanding these pathways is critical for identifying therapeutic targets and developing precision medicine strategies. This poster highlights the major molecular pathways implicated in GBM pathogenesis, their interactions, and emerging biomarkers that may guide future treatment approaches.

Our interactive glioblastoma pathway integrates molecular insights with validated biomarkers and antibody targets, giving you a comprehensive view of the tumor’s signaling landscape. Our poster highlights the major pathways involved in GBM pathogenesis, their spatial organization, and potential therapeutic targets. Plus, you can easily browse premium reagents to help move your glioblastoma research forward.